The retinitis pigmentosa market is propelled forward by advancements in gene therapy and innovative treatment modalities, offering promising prospects for slowing down the progression of this degenerative eye disease. Additionally, increasing research investments, growing awareness, and collaborative efforts among pharmaceutical companies contribute to the market's momentum, fostering a more optimistic landscape for patients and potential therapeutic breakthroughs.
LAS VEGAS, April 2, 2024 /PRNewswire/ -- DelveInsight's Retinitis Pigmentosa Market Insights report includes a comprehensive understanding of current treatment practices, retinitis pigmentosa emerging drugs, market share of individual therapies, and current and forecasted market size from 2020 to 2034, segmented into 7MM [the United States, the EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan].
Key Takeaways from the Retinitis Pigmentosa Market Report
- According to DelveInsight's analysis, the market size for retinitis pigmentosa reached USD 500 million in 2023 across the 7MM and is expected to grow with a significant CAGR by 2032.
- DelveInsight's analysis reveals that the overall prevalent population of retinitis pigmentosa in the 7MM was reported as 274K in 2023.
- Nonsyndromic retinitis pigmentosa is more prevalent than syndromic retinitis pigmentosa with 186,897 cases in 2023.
- Currently, LUXTURNA is the only approved therapy for retinitis pigmentosa and is only authorized for the treatment of a small subpopulation of patients that have the RPE65 mutation.
- From the drugs currently under development for the treatment of retinitis pigmentosa, several different class can be highlighted: cell therapies, gene therapies, optogenetic gene therapies, oligonucleotides (e.g. oligonucleotides, antisense oligonucleotides, and antisense ribonucleic acid interference (RNAi) oligonucleotides), antibodies, peptides, recombinant proteins and peptides, synthetic peptides, and small molecules.
- Out of all the potential therapies, market size of gene therapies contributes more than 70%, whereas small molecules and oligonucleotide contributes roughly 21% among overall revenue in 2034
- There are development of Gene and cell therapies with diverse targets like RHO, USH2A, and RPGR. Apart from cell and conventional form of gene therapies, Optogenetics also presents an innovative gene therapy overcoming the limitations of traditional approaches. There are several companies that have advanced optogenetic retinal gene therapies into clinical trials including, GenSight Biologics (GS030), Bionic Sight (BS01), and Nanoscope Therapeutics (MCO-010) Whereas jCyte's jCell is one of the leading cell therapies currently in Phase IIb stage of development.
- Leading retinitis pigmentosa companies such as Johnson & Johnson Innovative Medicine, MeiraGTx, Beacon Therapeutics, Nanoscope Therapeutics, Gensight Biologics, 4D Molecular Therapeutics, Coave Therapeutics, Ocugen, Bionic Sight, jCyte, Endogena Therapeutics, ProQR Therapeutics, Aldeyra Therapeutics, and others are developing novel retinitis pigmentosa drugs that can be available in the retinitis pigmentosa market in the coming years.
- Other promising retinitis pigmentosa therapies in the pipeline include Botaretigene sparoparvovec, AGTC-501, GS030, 4D 125, CTx PDE6B, OCU 400, EA-2353, Ultevursen, ADX 2191, and others.
Discover which therapies are expected to grab the major retinitis pigmentosa market share @ Retinitis Pigmentosa Market Report
Retinitis Pigmentosa Overview
Retinitis pigmentosa denotes a collection of hereditary retinal disorders that result in the degeneration of the retina and eventual blindness. The condition is marked by the gradual deterioration of both rod and cone photoreceptors, leading to night blindness and progressing visual field impairments. Subsequently, there is a gradual deterioration in central vision during daylight as a result of the diminished function of the less-sensitive cone photoreceptors. Often associated with genetic mutations, more than 44 genes have been identified in connection with retinitis pigmentosa. Inheritance patterns include recessive, dominant, or X-linked, and approximately 50% of cases involve unidentified mutations. The suspicion of retinitis pigmentosa arises in individuals with impaired night vision or a family history of the disorder. Retinitis pigmentosa diagnosis relies on the documentation of rod dysfunction, assessed through dark adaptation or electroretinogram, as well as the progressive decline in photoreceptor function, peripheral vision loss, and bilateral eye involvement. Ocular examination typically reveals preserved visual acuity until the advanced stages of the disease and diminished visual fields.
Retinitis Pigmentosa Epidemiology Segmentation
Among the 7MM, the total number of prevalent cases of retinitis pigmentosa in the US were ~113K in 2023.
In the 7MM, XLRP accounted for ~15% of the nonsyndromic retinitis pigmentosa.
Nonsyndromic retinitis pigmentosa is more prevalent than syndromic retinitis pigmentosa with ~65% cases of total retinitis pigmentosa.
The retinitis pigmentosa market report proffers epidemiological analysis for the study period 2020-2034 in the 7MM segmented into:
- Total Retinitis Pigmentosa Diagnosed Prevalent Population
- Retinitis Pigmentosa Gender-Specific Diagnosed Prevalence
- Retinitis Pigmentosa Type-Specific Diagnosed Prevalence
- Sub-Type Specific Diagnosed Prevalence of Syndromic and Systemic Retinitis Pigmentosa
- Sub-Type Specific Diagnosed Prevalence of Non-Syndromic Retinitis Pigmentosa
Retinitis Pigmentosa Treatment Market
Existing therapies for retinitis pigmentosa treatment are constrained, but several advancements are on the brink of entering the therapeutic landscape. According to randomized clinical trials involving vitamins and supplements, the primary widely endorsed intervention is supplementing with high doses of vitamin A palmitate and fish oil, while concurrently avoiding vitamin E. However, these modifications merely serve to postpone degeneration. The accessibility of the retina to relatively safe surgical procedures, coupled with the immune privilege of the eye, positions retinal diseases as an optimal context for deploying cutting-edge approaches like gene therapy and stem cell therapy. These innovative methods hold promise in yielding effective treatments for certain forms of retinitis pigmentosa.
Due to the numerous complications, diverse forms, and varying stages associated with retinitis pigmentosa, treatment approaches are now customized based on the specific types of retinitis pigmentosa and their inheritance patterns. In Japan, however, there is a notable absence of standardized, evidence-based, and comprehensive curative treatments for retinitis pigmentosa. Nevertheless, there is optimism as several novel treatments are currently in clinical development, aiming to decelerate or potentially reverse the degeneration of the retina caused by the loss of photoreceptors.
In contrast to the United States, EU-4, and the UK, Japan has experienced numerous therapy failures in the final stages of retinitis pigmentosa treatment development. Notably, Adaptinol has received approval in Japan for the treatment of retinitis pigmentosa. According to the treatment guidelines authored by Takahashi Masahiro et al., Adaptinol is considered an oral carotenoid presumed to exert effects similar to lutein. It is commonly used to temporarily enhance the visual field and dark adaptation in individuals with retinitis pigmentosa.
To know more about retinitis pigmentosa treatment guidelines, visit @ Retinitis Pigmentosa Management
Retinitis Pigmentosa Pipeline Therapies and Key Companies
- Botaretigene sparoparvovec: Johnson & Johnson Innovative Medicine /MeiraGTx
- AGTC-501: Beacon Therapeutics
- MCO-010: Nanoscope Therapeutics
- GS030: Gensight Biologics
- 4D 125: 4D Molecular Therapeutics
- CTx PDE6B: Coave Therapeutics
- OCU 400: Ocugen
- BS01: Bionic Sight
- jCell: jCyte
- EA-2353: Endogena Therapeutics
- Ultevursen: ProQR Therapeutics
- ADX 2191: Aldeyra Therapeutics
Learn more about the FDA-approved drugs for retinitis pigmentosa @ Drugs for Retinitis Pigmentosa Treatment
Retinitis Pigmentosa Market Dynamics
The dynamics of the retinitis pigmentosa market are expected to change in the coming years. Gene therapy, available in the market, is utilized to address the effects of defective, disease-causing genes by employing engineered viruses, or viral vectors, to deliver a functional gene version into cells. The rising prevalence of retinitis pigmentosa worldwide has spurred pharmaceutical companies to explore this market, aiming for enhanced revenues through specific research and development strategies. Multiple therapeutic targets exist, with Spark Therapeutics, a key player in the retinitis pigmentosa market, acquiring RhoNova in 2016 for a potential gene therapy targeting rhodopsin-linked autosomal dominant retinitis pigmentosa, an inherited retinal disease leading to visual impairment and, in severe cases, blindness.
Furthermore, many potential therapies are being investigated for the treatment of retinitis pigmentosa, and it is safe to predict that the treatment space will significantly impact the retinitis pigmentosa market during the forecast period. Moreover, the anticipated introduction of emerging therapies with improved efficacy and a further improvement in the diagnosis rate are expected to drive the growth of the retinitis pigmentosa market in the 7MM.
Moreover, retinitis pigmentosa treatment poses a significant economic burden and disrupts patients' overall well-being and QOL. Furthermore, the retinitis pigmentosa market growth may be offset by failures and discontinuation of emerging therapies, unaffordable pricing, market access and reimbursement issues, and a shortage of healthcare specialists. In addition, the undiagnosed, unreported cases and the unawareness about the disease may also impact the retinitis pigmentosa market growth.
Retinitis Pigmentosa Market Report Metrics | Details |
Study Period | 2020-2034 |
Coverage | 7MM [the United States, the EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan]. |
Retinitis Pigmentosa Market CAGR | 16.8 % |
Retinitis Pigmentosa Market Size in 2023 | USD 500 Million |
Key Retinitis Pigmentosa Companies | Johnson & Johnson Innovative Medicine, MeiraGTx, Beacon Therapeutics, Nanoscope Therapeutics, Gensight Biologics, 4D Molecular Therapeutics, Coave Therapeutics, Ocugen, Bionic Sight, jCyte, Endogena Therapeutics, ProQR Therapeutics, Aldeyra Therapeutics, and others |
Key Pipeline Retinitis Pigmentosa Therapies | Botaretigene sparoparvovec, AGTC-501, MCO-010, GS030, 4D 125, CTx PDE6B, OCU 400, BS01, jCell, EA-2353, Ultevursen, ADX 2191, and others |
Scope of the Retinitis Pigmentosa Market Report
- Therapeutic Assessment: Retinitis Pigmentosa current marketed and emerging therapies
- Retinitis Pigmentosa Market Dynamics: Key Market Forecast Assumptions of Emerging Retinitis Pigmentosa Drugs and Market Outlook
- Competitive Intelligence Analysis: SWOT analysis and Market entry strategies
- Unmet Needs, KOL's views, Analyst's views, Retinitis Pigmentosa Market Access and Reimbursement
Discover more about retinitis pigmentosa drugs in development @ Retinitis Pigmentosa Clinical Trials
Table of Contents
1 | KEY INSIGHTS |
2 | REPORT INTRODUCTION |
3 | EXECUTIVE SUMMARY OF RETINOPATHY OF PREMATURITY |
4 | KEY EVENTS |
5 | EPIDEMIOLOGY AND MARKET FORECAST METHODOLOGY |
6 | RETINOPATHY OF PREMATURITY MARKET OVERVIEW AT A GLANCE |
6.1 | MARKET SHARE (%) DISTRIBUTION BY THERAPIES IN THE 7MM IN 2019 |
6.2 | MARKET SHARE (%) DISTRIBUTION BY THERAPIES IN THE 7MM IN 2032 |
7 | DISEASE BACKGROUND AND OVERVIEW |
7.1 | INTRODUCTION |
7.2 | CAUSES |
7.3 | SIGN AND SYMPTOMS |
7.4 | PATHOPHYSIOLOGY |
7.5 | PATHOGENESIS |
7.6 | DIAGNOSIS |
7.7 | TREATMENT MANAGEMENT OF RETINOPATHY OF PREMATURITY |
7.8 | GUIDELINES FOR RETINOPATHY OF PREMATURITY |
7.8.1 | American Academy of Pediatrics (AAP): 2018 |
7.8.1.1 | Screening Guidelines |
7.8.1.2 | Treatment Guidelines |
7.8.2 | Royal College of Pediatrics and Child Health (RCPCH): 2022 |
7.8.2.1 | Screening Guidelines |
7.8.2.2 | Treatment Guidelines |
7.8.3 | Screening Guidelines in England, Germany, France, and Italy |
7.8.4 | Japanese Ophthalmological Society: 2020 |
7.8.4.1 | Guidelines for Follow-up after Intravitreal Injection of Ranibizumab |
8 | EPIDEMIOLOGY AND PATIENT POPULATION OF THE 7MM |
8.1 | KEY FINDINGS |
8.2 | ASSUMPTIONS AND RATIONALE |
8.3 | TOTAL INCIDENT CASES OF RETINOPATHY OF PREMATURITY IN THE 7MM |
8.4 | UNITED STATES |
8.4.1 | Total Incident Cases of Preterm Infants by Birth Weight (=1,500g) in the United States |
8.4.2 | Total Incident Cases of Retinopathy of Prematurity in the United States |
8.4.3 | Total Treated Cases of Retinopathy of Prematurity in the United States |
8.5 | EU4 AND THE UK |
8.5.1 | Total Incident Cases of Preterm Infants by Birth Weight (=1,500g) in EU4 and the UK |
8.5.2 | Total Incident Cases of Retinopathy of Prematurity in EU4 and the UK |
8.5.3 | Total Treated Cases of Retinopathy of Prematurity in EU4 and the UK |
8.6 | JAPAN |
8.6.1 | Total Incident Cases of Preterm Infants by Birth Weight (=1,500g) in Japan |
8.6.2 | Total Incident Cases of Retinopathy of Prematurity in Japan |
8.6.3 | Total Treated Cases of Retinopathy of Prematurity in Japan |
9 | PATIENT JOURNEY |
10 | MARKETED DRUGS |
10.1 | KEY COMPETITORS |
10.2 | LUCENTIS (RANIBIZUMAB): NOVARTIS |
10.2.1 | Product Description |
10.2.2 | Regulatory Milestones |
10.2.3 | Other Development Activities |
10.2.4 | Pivotal Clinical Trial |
10.2.5 | Product Profile |
10.3 | EYLEA (AFLIBERCEPT): REGENERON/BAYER |
10.3.1 | Product Description |
10.3.2 | Regulatory Milestones |
10.3.3 | Other Development Activities |
10.3.4 | Pivotal Clinical Trial |
10.3.5 | Product Profile |
11 | KEY COMPETITORS FOR PRE-CLINICAL ASSETS |
12 | RETINOPATHY OF PREMATURITY: 7MM ANALYSIS |
12.1 | KEY FINDINGS |
12.2 | KEY MARKET FORECAST ASSUMPTIONS |
12.3 | MARKET OUTLOOK |
12.4 | TOTAL MARKET SIZE OF RETINOPATHY OF PREMATURITY IN THE 7MM |
12.5 | UNITED STATES MARKET SIZE |
12.5.1 | Total Market Size of Retinopathy of Prematurity in the United States |
12.5.2 | Market Size of Retinopathy of Prematurity by Current and Emerging Therapies in the United States |
12.6 | EU4 AND THE UK MARKET SIZE |
12.6.1 | Total Market Size of Retinopathy of Prematurity in EU4 and the UK |
12.6.2 | Market Size of Retinopathy of Prematurity by Current and Emerging Therapies in EU4 and the UK |
12.7 | JAPAN MARKET SIZE |
12.7.1 | Total Market Size of Retinopathy of Prematurity in Japan |
12.7.2 | Market Size of Retinopathy of Prematurity by Current and Emerging Therapies in Japan |
13 | UNMET NEEDS |
14 | SWOT ANALYSIS |
15 | KOL VIEWS |
16 | MARKET ACCESS AND REIMBURSEMENT |
16.1 | UNITED STATES |
16.1.1 | Centre for Medicare & Medicaid Services (CMS) |
16.2 | EU4 AND THE UK |
16.2.1 | Germany |
16.2.2 | France |
16.2.3 | Italy |
16.2.4 | Spain |
16.2.5 | United Kingdom |
16.3 | JAPAN |
16.3.1 | MHLW |
16.4 | REIMBURSEMENT OF RETINOPATHY OF PREMATURITY |
16.4.1 | EYLEA (aflibercept): Regeneron Pharmaceuticals/Bayer |
16.4.2 | LUCENTIS (ranibizumab): Novartis |
17 | APPENDIX |
17.1 | BIBLIOGRAPHY |
17.2 | REPORT METHODOLOGY |
18 | DELVEINSIGHT CAPABILITIES |
19 | DISCLAIMER |
Related Reports
Retinitis Pigmentosa Pipeline
Retinitis Pigmentosa Pipeline Insight - 2024 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key retinitis pigmentosa companies, including Acucela Inc, Allergan Plc, Amarantus Bioscience Holdings Inc, Amgen Inc, Applied Genetic Technologies Corp, Asklepios BioPharmaceutical Inc, Astellas Pharma Inc, Caladrius Biosciences Inc, Dompe Farmaceutici SpA, GenSight Biologics SA, Grupo Ferrer Internacional SA, IDPharma Co Ltd, Janssen Pharmaceutical, MeiraGTx, Anabasis Pharma, Allegro Ophthalmics, Nacuity Pharmaceuticals, ReNeuron, jCyte, Editas Medicine, SanBio, NightstarTherapeutics, Biogen, OiDE OptoEye, among others.
Retinitis Pigmentosa Epidemiology Forecast
Retinitis Pigmentosa Epidemiology Forecast - 2032 report delivers an in-depth understanding of the disease, historical and forecasted retinitis pigmentosa epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
X-Linked Retinitis Pigmentosa Market
X-Linked Retinitis Pigmentosa Market Insights, Epidemiology, and Market Forecast - 2032 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, market share of the individual therapies, and key X-linked retinitis pigmentosa companies including Biogen, 4D Molecular therapeutics, Applied Genetics Technology Corporation, among others.
X-Linked Retinitis Pigmentosa Pipeline
X-Linked Retinitis Pigmentosa Pipeline Insight - 2024 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key X-linked retinitis pigmentosa companies, including Biogen, 4D Molecular therapeutics, Applied Genetics Technology Corporation,among others.
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.
Contact Us
Shruti Thakur
info@delveinsight.com
+14699457679
www.delveinsight.com
Logo: https://mma.prnewswire.com/media/1082265/3528414/DelveInsight_Logo.jpg
View original content:https://www.prnewswire.co.uk/news-releases/retinitis-pigmentosa-market-to-grow-rapidly-at-a-cagr-of-16-8-by-2034--delveinsight-302105884.html
